Gene signature may help guide initial CLL treatment choiceNovember 14, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
Foundation launches direct-to-patient registry in multiple myelomaNovember 13, 2019Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019DLBCLLymphoma & Plasma Cell DisordersFollicular LymphomaImmunotherapyImmuno-oncology
Survival ‘excellent’ after rituximab-bendamustine induction in transplant-eligible MCLNovember 6, 2019Lymphoma & Plasma Cell Disorders
Levofloxacin prophylaxis improves survival in newly diagnosed myelomaNovember 1, 2019Lymphoma & Plasma Cell Disorders
Consider renal function in TLS risk assessment of venetoclax-treated CLLOctober 29, 2019Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
FDA proposes new breast implant labeling with a boxed warningOctober 24, 2019Patient & Survivor CareLymphoma & Plasma Cell Disorders
SEER analysis reveals medication adherence factors in newly diagnosed myelomaOctober 24, 2019Lymphoma & Plasma Cell Disorders
Pembrolizumab shows promise for relapsed/refractory PMBCLOctober 24, 2019Lymphoma & Plasma Cell DisordersImmuno-oncology
Vitamin D deficiency appears to worsen survival in Hodgkin lymphomaOctober 17, 2019Lymphoma & Plasma Cell Disorders
Ibrutinib linked to hypertension in B-cell malignanciesOctober 15, 2019Lymphoma & Plasma Cell Disorders
Best treatment approach for early stage follicular lymphoma is unclearOctober 9, 2019Follicular LymphomaLymphoma & Plasma Cell Disorders
Follow-up shows favorable results with acalabrutinib in MCLOctober 8, 2019Lymphoma & Plasma Cell Disorders
What is the optimal duration of maintenance in myeloma?October 8, 2019Lymphoma & Plasma Cell Disorders
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLLOctober 3, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
